These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 11594570)

  • 1. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma.
    Foss FM
    Ann N Y Acad Sci; 2001 Sep; 941():166-76. PubMed ID: 11594570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies.
    Nichols J; Foss F; Kuzel TM; LeMaistre CF; Platanias L; Ratain MJ; Rook A; Saleh M; Schwartz G
    Eur J Cancer; 1997 Jan; 33 Suppl 1():S34-6. PubMed ID: 9166099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication.
    Foss FM; Bacha P; Osann KE; Demierre MF; Bell T; Kuzel T
    Clin Lymphoma; 2001 Mar; 1(4):298-302. PubMed ID: 11707845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma.
    Foss FM
    Clin Lymphoma; 2000 Sep; 1(2):110-6; discussion 117. PubMed ID: 11707818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides.
    Saleh MN; LeMaistre CF; Kuzel TM; Foss F; Platanias LC; Schwartz G; Ratain M; Rook A; Freytes CO; Craig F; Reuben J; Sams MW; Nichols JC
    J Am Acad Dermatol; 1998 Jul; 39(1):63-73. PubMed ID: 9674399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing denileukin diftitox (Ontak) therapy.
    Duvic M; Talpur R
    Future Oncol; 2008 Aug; 4(4):457-69. PubMed ID: 18684057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal Antibodies.
    Geskin LJ
    Dermatol Clin; 2015 Oct; 33(4):777-86. PubMed ID: 26433849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms.
    Duvic M
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S51-5. PubMed ID: 11707865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-2 receptor-directed therapies for cutaneous lymphomas.
    Foss FM; Waldmann TA
    Hematol Oncol Clin North Am; 2003 Dec; 17(6):1449-58. PubMed ID: 14710895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DAB(389)IL-2 (denileukin diftitox, ONTAK): review of clinical trials to date.
    Kuzel TM
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S33-6. PubMed ID: 11707861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DAB(389)IL-2 (denileukin diftitox, ONTAK): other potential applications.
    LeMaistre CF
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S37-40. PubMed ID: 11707862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ontak-like human IL-2 fusion toxin.
    Wang Z; Zheng Q; Zhang H; Bronson RT; Madsen JC; Sachs DH; Huang CA; Wang Z
    J Immunol Methods; 2017 Sep; 448():51-58. PubMed ID: 28551309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denileukin diftitox.
    Figgitt DP; Lamb HM; Goa KL
    Am J Clin Dermatol; 2000; 1(1):67-72; discussion 73. PubMed ID: 11702307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two novel therapies for the treatment of cutaneous T-cell lymphoma.
    LeMaistre CF
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S7. PubMed ID: 11707856
    [No Abstract]   [Full Text] [Related]  

  • 15. Initial clinical experiences with an interleukin-2 fusion toxin (DAB486-IL-2).
    Meneghetti CM; LeMaistre CF
    Targeted Diagn Ther; 1992; 7():395-401. PubMed ID: 1633301
    [No Abstract]   [Full Text] [Related]  

  • 16. Bilateral adrenal hemorrhage and adrenal insufficiency in a patient with lymphomatous adrenal infiltration following administration of a fusion toxin (DAB486 interleukin-2).
    Cohen R; Jaffe ES; Stetler-Stevenson MA; Sausville EA; DeNigris EC; Woodworth T; Foss FM
    J Immunother Emphasis Tumor Immunol; 1994 Oct; 16(3):229-33. PubMed ID: 7834123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denileukin diftitox: a concise clinical review.
    Eklund JW; Kuzel TM
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):33-8. PubMed ID: 15757436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox.
    Chin KM; Foss FM
    Clin Lymphoma Myeloma; 2006 Nov; 7(3):199-204. PubMed ID: 17229335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapies: Denileukin diftitox--a step towards a 'magic bullet' for CTCL.
    Kadin ME; Vonderheid EC
    Nat Rev Clin Oncol; 2010 Aug; 7(8):430-2. PubMed ID: 20668480
    [No Abstract]   [Full Text] [Related]  

  • 20. Bispecific human IL2-CCR4 immunotoxin targets human cutaneous T-cell lymphoma.
    Wang H; Wang Z; Zhang H; Qi Z; Johnson AC; Mathes D; Pomfret EA; Rubin E; Huang CA; Wang Z
    Mol Oncol; 2020 May; 14(5):991-1000. PubMed ID: 32107846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.